X

Trial Profile

A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelareorep (Primary) ; Docetaxel; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

Most Recent Events

06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
17 May 2017 According to an Oncolytics Biotech Inc. media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
17 May 2017 Results published in the Oncolytics Biotech Inc. media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com